中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2013年
23期
37-37,38
,共2页
阿德福韦酯%拉米夫定%代偿期乙型肝炎肝硬化%疗效
阿德福韋酯%拉米伕定%代償期乙型肝炎肝硬化%療效
아덕복위지%랍미부정%대상기을형간염간경화%료효
Adefovir dipivoxil%Lamivudine%Decompensated liver cirrhosis after hepatitis B%Curative effect
目的：探讨阿德福韦酯与拉米夫定联合治疗代偿期乙型肝炎肝硬化的疗效。方法：选择代偿期乙肝肝硬化血清HBV DNA阳性患者60例，随机分为观察组和对照组，各30例。观察组给予阿德福韦酯与拉米夫定联合治疗，对照组给予阿德福韦酯治疗，观察两组治疗前及治疗后的12、24、48周肝功能和HBV DNA定量。结果：48周时观察组ALT恢复率明显高于对照组，两组比较差异有统计学意义(P<0.05)；血清HBV-DNA复制改善情况观察组显著优于对照组，两组比较差异有统计学意义(P<0.05)。结论：阿德福韦酯与拉米夫定联合治疗代偿期乙型肝炎肝硬化可有效抑制乙肝病毒复制、明显控制病情进展和改善预后，值得临床借鉴。
目的：探討阿德福韋酯與拉米伕定聯閤治療代償期乙型肝炎肝硬化的療效。方法：選擇代償期乙肝肝硬化血清HBV DNA暘性患者60例，隨機分為觀察組和對照組，各30例。觀察組給予阿德福韋酯與拉米伕定聯閤治療，對照組給予阿德福韋酯治療，觀察兩組治療前及治療後的12、24、48週肝功能和HBV DNA定量。結果：48週時觀察組ALT恢複率明顯高于對照組，兩組比較差異有統計學意義(P<0.05)；血清HBV-DNA複製改善情況觀察組顯著優于對照組，兩組比較差異有統計學意義(P<0.05)。結論：阿德福韋酯與拉米伕定聯閤治療代償期乙型肝炎肝硬化可有效抑製乙肝病毒複製、明顯控製病情進展和改善預後，值得臨床藉鑒。
목적：탐토아덕복위지여랍미부정연합치료대상기을형간염간경화적료효。방법：선택대상기을간간경화혈청HBV DNA양성환자60례，수궤분위관찰조화대조조，각30례。관찰조급여아덕복위지여랍미부정연합치료，대조조급여아덕복위지치료，관찰량조치료전급치료후적12、24、48주간공능화HBV DNA정량。결과：48주시관찰조ALT회복솔명현고우대조조，량조비교차이유통계학의의(P<0.05)；혈청HBV-DNA복제개선정황관찰조현저우우대조조，량조비교차이유통계학의의(P<0.05)。결론：아덕복위지여랍미부정연합치료대상기을형간염간경화가유효억제을간병독복제、명현공제병정진전화개선예후，치득림상차감。
Objective:To investigate the adefovir dipivoxil combined with lamivudine treatment for decompensated cirrhosis of hepatitis curative ef ect.Method:Choose compensatory period of 60 patients with hepatitis b cirrhosis serum HBV DNA positive,were randomly divided into observation group and control group,30 cases each. Observation group was given lamivudine and adefovir combination therapy,the control group given adefovir ester treatment,observe the two groups before treatment and 12, 24 and 48 weeks after treatment of liver function and HBV DNA ration.Result:At 8 weeks ALT recovery rate of observation group was obviously higher than that of control group,two groups compare difference was statistically significant (P<0.05);Serum HBV-DNA replication improvement group was significantly better than control group, two groups of comparisons difference was statistically significant (P<0.05).Conclusion:Lamivudine and adefovir combination therapy compensatory phase of hepatitis b cirrhosis of the liver can effectively inhibit HBV replication and obvious control disease progression and improve prognosis,is worthy of reference for clinical.
